Results 121 to 130 of about 10,401 (200)

Reappraising the clinical impact of mepolizumab [PDF]

, 2017
Chupp, Jones, Jones, Juniper, Santanello, Wenzel   +5 more
core   +2 more sources

Clinical Impact of Mepolizumab on Airway Mucus Plugs in Patients with Severe Asthma. [PDF]

J Asthma Allergy
Hara Y, Tanabe N, Marumo S, Murohashi K, Hayashi Y, Nagata M, Asada T, Nagaoka S, Kobayashi N, Hirai T, Kaneko T.   +10 more
europepmc   +1 more source

Protocol for an open labelled observational study in children & adolescents with severe asthma with an eosinophilic phenotype treated with mepolizumab (CASAM). [PDF]

PLoS One
Gupta A, de Mir Messa I, Valverde-Molina J, Murray CS, Moral L, Torres Borrego J, Pike K, Díaz-Izquierdo A, Martínez-Cañavate A, Nagakumar P, Cook J, Gupta L, CASAM Group.   +12 more
europepmc   +1 more source

Mepolizumab treatment is associated with physical activity and cardiorespiratory fitness irrespective of endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps: a randomised controlled trial. [PDF]

Eur Clin Respir J
Jens T, Morten H, Anne-Sophie H, Lukas M, Kasper A, Howraman M, Vibeke B.   +6 more
europepmc   +1 more source

Refractory erythroderma in idiopathic hypereosinophilic syndrome: A case treated with mepolizumab and abrocitinib. [PDF]

SAGE Open Med Case Rep
Elhaj H, Al Amari A, Alyaqout F, Ben-Shoshan M, Netchiporouk E, Fein M.   +5 more
europepmc   +1 more source

Efficacy and safety of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis. [PDF]

J Thorac Dis
Li Y, Li J, Yang H, Wu L.
europepmc   +1 more source

The pediatric asthma yardstick: Practical recommendations for a sustained step-up in asthma therapy for children with inadequately controlled asthma [PDF]

, 2018
Bacharier, Leonard B, Chipps, Bradley E, Farrar, Judith R, Jackson, Daniel J, Murphy, Kevin R, Phipatanakul, Wanda, Szefler, Stanley J, Teague, W. Gerald, Zeiger, Robert S   +8 more
core   +2 more sources

Proteomic Identification of Plasma Biomarkers of Response to IL-5 Inhibitor Biologics in Healthy Subjects. [PDF]

Clin Transl Sci
Chekka LMS, Samarth DP, Howard KE, Guo Y, Mohamed EG, Decker E, Wheeler W, Wommack J, Gogain J, Deering J, Schrieber SJ, Wang YM, Strauss DG, Florian J, Hyland PL.   +14 more
europepmc   +1 more source

Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma. [PDF]

Front Immunol
Miguéns-Suárez P, Martelo-Vidal L, Vázquez-Mera S, Blanco-Aparicio M, Calvo-Álvarez U, González-Fernández C, Mosteiro-Añón M, Corbacho-Abelaira D, Hermida-Valverde T, Calvo-Henríquez C, Nieto-Fontarigo JJ, Salgado FJ, González-Barcala FJ.   +12 more
europepmc   +1 more source

Real-world outcomes after anti-IL-5/anti-IL-5Rα treatment for hypereosinophilic syndrome: Systematic literature review. [PDF]

J Allergy Clin Immunol Glob
Jain P, Rowell J, Edmonds C, Stokes M, Ding N, Chen SY.   +5 more
europepmc   +1 more source